Pharmacokinetic study of levonorgestrel used as a postcoital agent.
The pharmacokinetics and pharmacodynamics of levonorgestrel (LNG) were studied in six women given 0.75 mg LNG orally for seven days during the periovulatory phase of the menstrual cycle. Steady-state concentrations of LNG were reached within three days and serum LNG concentrations at various times on day 7 were generally lower than on day 1, presumably due to a reduced serum level of SHBG. On day 7 the volume of distribution was significantly increased and Co significantly decreased and both the clearance and elimination half-life were higher on day 7 than on day 1. Half-lives varied from 5.6 to 25.1 hours. The day-to-day intra-subject variations in serum LNG concentrations ranged from 23% to 80%. Serum concentrations of pituitary and ovarian hormones suggested that ovulation was not inhibited in four of the six subjects and was delayed in the remaining two. No significant changes in serum prolactin levels were observed.
D000042:Absorption; D000328:Adult; D003277:Contraceptives, Oral, Combined; D003281:Contraceptives, Postcoital; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006207:Half-Life; D006801:Humans; D016912:Levonorgestrel; D007986:Luteinizing Hormone / Q000097:blood; D009644:Norgestrel / Q000493:pharmacokinetics* / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood
D003277:Contraceptives, Oral, Combined; D003281:Contraceptives, Postcoital; D009644:Norgestrel; D011374:Progesterone; D004958:Estradiol; D016912:Levonorgestrel; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone